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Pål Hasvold, MSc Pharm,e Saga Johansson, MD, PhD,e Marcus Thuresson, PhD,f and
Joakim Nordanstig, MD, PhD,g Karlstad, Stockholm, Uppsala, Gothenburg, and Mölndal, Sweden
Objective: Peripheral artery disease (PAD) is common worldwide, and PAD patients are increasingly offered lower limb
revascularization procedures. The aim of this population-based study was to describe the current risk for cardiovascular
(CV) events and mortality and also to elucidate the current pharmacologic treatment patterns in revascularized lower limb
PAD patients.
Methods: This observational, retrospective cohort study analyzed prospectively collected linked data retrieved from
mandatory Swedish national health care registries. The Swedish National Registry for Vascular Surgery database was used
to identify revascularized PAD patients. Current risk for CV events and death was analyzed, as were prescribed drugs
aimed for secondary prevention. A Cox proportional hazard regression model was used to explore risk factors for
suffering a CV event.
Results: Between May 2008 and December 2013, there were 18,742 revascularized PAD patients identiﬁed. Mean age was
70.0 years among patients with intermittent claudication (IC; n[ 6959) and 76.8 years among patients with critical limb
ischemia (CLI; n [ 11,783). Antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors/angiotensin re-
ceptor blockers, and beta-blockers were used by 73%, 60%, 57%, and 49% at admission for revascularization. CV event rate
(a composite of myocardial infarction, ischemic stroke, or CV death) at 12, 24, and 36 months was 5.1% (95% conﬁdence
interval [CI], 4.5-5.6), 9.5% (95% CI, 8.7-10.3), and 13.8% (95% CI, 12.8-14.8) in patients with IC and 16.8% (95% CI,
16.1-17.6), 25.9% (95% CI, 25.0-26.8), and 34.3% (95% CI, 33.2-35.4) in patients with CLI. Best medical treatment,
deﬁned as any antiplatelet or anticoagulant therapy along with statin treatment, was offered to 65% of IC patients and
45% of CLI patients with little change during the study period. Statin therapy was associated with reduced CV events
(hazard ratio, 0.76; 95% CI, 0.71-0.81; P < .001), whereas treatment with low-dose aspirin was not.
Conclusions: Revascularized PAD patients are still at a high risk for CV events without a declining time trend. A large
proportion of both IC and CLI patients were not offered best medical treatment. The most commonly used agent was
aspirin, which was not associated with CV event reduction. This study calls for improved medical management and high-
lights an important and partly unmet medical need among revascularized PAD patients. (J Vasc Surg 2016;64:1009-17.)Peripheral artery disease (PAD) represents a common of guidelines providing physicians with recommendations
health problem affecting millions of people worldwide.1
The prevalence in Sweden is estimated to be nearly 20%
among people older than 60 years.2
Because of the polyvascular nature of atherosclerotic
disease, PAD patients have a high risk for cardiovascular
(CV) events and premature death.3-5 Treatment strategies
in PAD are therefore targeted against risk factors for CV
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territories.13
A large and increasing number of PAD patients are
currently offered revascularization, mainly because of the
rapid development and availability of modern, minimally
invasive endovascular revascularization techniques.5,14,15
In this deﬁned population of patients, reliable modern
data regarding the risk for short- and long-term CV events
and associated risk factors for suffering such events are
scarce. Also, information on how pharmacologic treatment
actually provided to these patients inﬂuences CV risk con-
stitutes an important piece of the puzzle in deciding on the
best medical management for the individual PAD patient.4
This observational study aimed to describe the contem-
porary incidence and risk factors for CV events and mortal-
ity in a large cohort of revascularized PAD patients,
retrieved from mandatory population-based registries in
Sweden. It further aimed to describe the current secondary
drug prevention treatment, and treatment persistence, in
revascularized PAD patients in a population-based setting.
The hypothesis was that CV event rates are still high in this
group of patients and that recommended secondary
preventive drugs are underused among PAD patients.
METHODS
Data sources
This observational cohort study analyzed prospectively
collected data retrieved from mandatory Swedish national
health care registries. The Swedish National Board of
Health and Welfare performed data linkage by using the
unique and mandatory personal identiﬁcation numbers
entailing full coverage of the Swedish health care system.
Swedish National Registry for Vascular Surgery.
The Swedish Vascular Surgery Registry (Swedvasc)15,16 is the
world’s oldest national vascular registry, launched in 1987,
with full coverage of all centers performing vascular surgery in
Sweden since 1994. The registry prospectively collects basic
characteristics and periprocedural and follow-up data for all
vascular procedures in Sweden, and data are entered into the
registry by vascular surgeons and nurses. The registry has
repeatedly been validated with high data accuracy.17,18
Data on PAD stage (ie, intermittent claudication [IC]
and critical limb ischemia [CLI]), smoking status, and type
of procedure (open and endovascular) were retrieved from
this registry.
National Patient Register. The National Patient
Register includes all primary and secondary diagnoses
recorded within Swedish hospitals regarding inpatient care
and in-hospital-based ambulatory care. Participation in the
registry is mandatory for all county council caregivers. The
International Classiﬁcation of Diseases, Tenth Revision
(ICD-10) has been used for coding of diagnoses since 1997.
The National Patient Register is updated once a year and
covers >99% of all hospital discharges.19 From this registry,
data on comorbidity and events were retrieved.
Cause of Death Register. The Cause of Death Regis-
ter contains data on all deaths in Sweden since 1961. Datacollected include time of death and underlying and
contributing causes of death, in addition to about 30 other
variables. The use of the Cause of Death Register, in com-
bination with the National Patient Register, has previously
been demonstrated to provide highly accurate data in
studies performed on similar populations of patients.20
Prescribed Drug Register. The Prescribed Drug Reg-
ister was launched July 1, 2005. The register provides data
on dispensed item (substance and formulation), dispensed
amount, data of dispensing, and prescriber and is updated
monthly.21 All drugs are classiﬁed according to the
Anatomical Therapeutic Chemical classiﬁcation system.
Data extraction and synthesis
Patient-level Swedvasc data were cross-referenced with
the other studied data sources (National Patient Register,
Cause of Death Register, and Prescribed Drug Register),
based on the unique personal identiﬁcation numbers, and
the predeﬁned study variables were subsequently extracted
from the different data sources. After completion of the
cross-referenced database, the personal identity numbers
were exchanged to anonymous study numbers.
Study population
All individuals >50 years who had undergone lower
limb revascularization for chronic PAD were eligible for
study inclusion and were identiﬁed in a Swedvasc data set
ranging from May 2008 to December 2013.
The date of the ﬁrst recorded procedure code of lower
limb revascularization during the speciﬁed time period (not
necessarily the patient’s ﬁrst lower limb revascularization)
was deﬁned as the revascularized PAD index event. PAD
stage (IC and CLI) was identiﬁed on the basis of the
recorded indication for revascularization in the Swedvasc
registry. Diagnoses before the index event were included
in the baseline data (Supplementary Table I, online only).
The baseline medication catchment period was deﬁned as
medications dispensed within 4 months prior and until
the day before the index event. Patients concomitantly
treated with statins in combination with antiplatelets or an-
ticoagulants were considered to have received best medical
treatment (BMT), and this proportion was calculated at
baseline as well as within 3 months after the index event.
Outcomes
Event rate. The primary end point was deﬁned as a
composite of nonfatal myocardial infarction (ICD-10:
I21), nonfatal ischemic stroke (ICD-10: I63-I64), or CV
death (all primary causes of death diagnosed with ICD-10
codes I00-I99). If one patient had several end points, only
the ﬁrst was used in the time-to-event analysis. Separate
analysis was performed for the individual components of
the composite end point.
All-cause mortality was deﬁned as death of any cause
after the index date.
Medication persistence. Persistence to major drug
classes (Supplementary Table II, online only) aimed for
CV secondary prevention was described for the year before
Table I. Baseline demographic and clinical characteristics for intermittent claudication (IC) and critical limb ischemia
(CLI) patients at admission for revascularization
IC (n ¼ 6959) CLI (n ¼ 11,783) Total (N ¼ 18,742)
Sex
Male 3798 (54.6) 5806 (49.3) 9604 (51.2)
Female 3161 (45.4) 5977 (50.7) 9138 (48.8)
Age, years
Mean (SD) 70.0 (8.3) 76.8 (9.6) 74.3 (9.7)
Median 70 78 74
Smoking statusa
Current smoker 433 (6.2) 1537 (13.0) 1970 (10.5)
Former smoker 1919 (27.6) 3077 (26.1) 4996 (26.6)
Never smoked 531 (7.6) 2229 (18.9) 2760 (14.7)
Missing data/unknown status 4076 (58.6) 4940 (41.9) 9016 (48.1)
Comorbidityb
Hypertension 5650 (81.2) 10,111 (85.8) 15,761 (84.1)
Unstable angina/angina pectoris 2386 (34.3) 4114 (34.9) 6500 (34.7)
Myocardial infarction 1011 (14.5) 2386 (20.2) 3397 (18.1)
Heart failure 754 (10.8) 3473 (29.5) 4227 (22.6)
Atrial ﬁbrillation 775 (11.1) 3124 (26.5) 3899 (20.8)
Ischemic stroke 523 (7.5) 1774 (15.1) 2297 (12.3)
TIA 387 (5.6) 837 (7.1) 1224 (6.5)
Diabetes 1957 (28.1) 5319 (45.1) 7276 (38.8)
Chronic obstructive pulmonary disease 867 (12.5) 1682 (14.3) 2549 (13.6)
Chronic renal insufﬁciency 183 (2.6) 730 (6.2) 913 (4.9)
Renal artery stenosis 105 (1.5) 142 (1.2) 247 (1.3)
Aortic aneurysm 448 (6.4) 489 (4.2) 937 (5.0)
Arterial embolism and thrombosis 69 (1.0) 150 (1.3) 219 (1.2)
Pulmonary embolism 82 (1.2) 245 (2.1)
Major organ-speciﬁc bleedings 454 (6.5) 1452 (12.3) 1906 (10.2)
Cancer 1208 (17.4) 2467 (20.9) 3675 (19.6)
Dementia 28 (0.4) 339 (2.9) 367 (2.0)
SD, Standard deviation; TIA, transient ischemic attack.
Data are presented as number (%) unless otherwise indicated.
aRegister data from Swedvasc.
bData from National Patient Register.
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At each day, the proportion of patients taking each speciﬁc
drugwas calculated among the patients still in the study. The
treatment duration of each dispense depended on the
number of pills as well as the number of pills taken (dose) per
day. If a patient had a treatment gap of>30 days, the patient
was deﬁned as a nonuser from the last calculated day with
available drug. Furthermore, if the same drug was again
dispensed to a patientwith a treatment gap during follow-up,
the patientwas deﬁned as a user from that actual date; and if a
patient was switched to another type of drugwithin the same
drug class after the revascularized PAD index event, the
patient was deﬁned as a user. For opioids, which are used
more intermittently, the proportion of patients with any
dispense within a speciﬁc 3-month interval was calculated.
Statistical analysis
Descriptive statistics are presented for demographic and
baseline variables as mean6 standard deviation and absolute
and relative frequencies. Time-to-event end points were
analyzed using a Cox proportional hazards model
comparing the two study groups with adjustment for type
of procedure (open vs endovascular), sex, age, calendar
year, prior CV disease (myocardial infarction, ischemicstroke, or unstable angina pectoris), diabetes, and indication
of BMT. In addition, univariate and multivariate Cox
regression procedures were performed to explore factors
related to the risk of the primary composite end point.
The analysis was performed in three steps. At ﬁrst, a series
of univariate analyses were performed for each predeﬁned
risk factor. In a second step, factors with a P value < .2
were selected and entered into a multivariate analysis. In
the third step, a backward stepwise procedure was applied
in which the best model was deﬁned as the model with
the smallest Akaike information criterion value. The proce-
dure was performed separately for each study group. Statis-
tical programming and analyses were performed using SAS
version 9.3 (SAS Institute, Cary, NC) and R version 3.2.2.22
Ethical considerations
Ethical approval was obtained from the Regional
Ethical Review Board at the University of Gothenburg
(reference number 649-14). The data sets from the
different national registers were received after a formal con-
sent from the registry stakeholders (National Steering
Committee of the Swedvasc and the Swedish National
Board of Health and Welfare, respectively), according to
the formal requirements of the registries.
Table II. Medication use for intermittent claudication (IC) and critical limb ischemia (CLI) patients at admission for
revascularization
IC (n ¼ 6959) CLI (n ¼ 11,783) Total (N ¼ 18,742)
Low-dose acetylsalicylic acida 5116 (73.5) 7245 (61.5) 12,361 (66.0)
Clopidogrel 527 (7.6) 827 (7.0) 1354 (7.2)
Warfarin 376 (5.4) 1250 (10.6) 1626 (8.7)
Heparin 272 (3.9) 924 (7.8) 1196 (6.4)
Cilostazol 131 (1.9) 60 (0.5) 191 (1.0)
Statins 5044 (72.5) 6172 (52.4) 11,216 (59.8)
Fibrates 73 (1.0) 54 (0.5) 127 (0.7)
Beta-blockers 3070 (44.1) 6018 (51.1) 9088 (48.5)
ACEIs 2299 (33.0) 4184 (35.5) 6483 (34.6)
ARBs 1674 (24.1) 2523 (21.4) 4197 (22.4)
Calcium channel blockers 2658 (38.2) 3708 (31.5) 6366 (34.0)
Diuretics 2000 (28.7) 6247 (53.0) 8247 (44.0)
Nitrates 1007 (14.5) 2412 (20.5) 3419 (18.2)
Oral antidiabetic drugs 1043 (15.0) 1972 (16.7) 3015 (16.1)
Insulin 895 (12.9) 3117 (26.5) 4012 (21.4)
Opioids 1193 (17.1) 7016 (59.5) 8209 (43.8)
Mild opioids 838 (12.0) 3625 (30.8) 4463 (23.8)
Strong opioids 479 (6.9) 4948 (42.0) 5427 (29.0)
BMT for PADb 4524 (65.0) 5305 (45.0) 9829 (52.4)
ACEIs, Angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; BMT, best medical treatment; PAD, peripheral artery disease.
Data from the Prescribed Drug Register. Data are presented as number (%).
aDual antiplatelet treatment: n ¼ 974 (IC and CLI, 5.4% and 5.1%).
bBMT was deﬁned as treatment with any antiplatelet or anticoagulant and statin.
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Baseline data and comorbidity. The ﬁnal analyzed
data set contained 18,742 patients, of whom 6959 (37%)
had IC and 11,783 (63%) had CLI. Demographic data
and previous medical history are given in Table I. Mean
age at the index lower limb revascularization was 70.0 years
for patients with IC and 76.8 years for patients with CLI.
Age distribution in 5-year intervals for the two groups is
presented in the Supplementary Fig (online only). Time
interval between ﬁrst PAD diagnosis and revascularization
differed between PAD stages, as the median time between
diagnosis and index revascularization was 193 (range,
0-5900) days in IC and 80 (range, 0-6063) days in CLI.
CV disease was common for both IC and CLI patients,
and almost half of the CLI patients had diabetes (Table I).
Antiplatelets, statins, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers (ACEIs/ARBs),
and beta-blockers were used by 73%, 60%, 57%, and 49%
of patients at admission for the index revascularization
(Table II).
CV events and all-cause mortality. Event rate of the
primary composite end point (nonfatal myocardial infarc-
tion, nonfatal ischemic stroke, or CV death) at 12, 24,
and 36 months was 5.1%, 9.5%, and 13.8% for subjects
with IC and 16.8%, 25.9%, and 34.3% for subjects with
CLI (Fig 1).
Event rate of CV-related mortality at 12, 24, and
36 months was 1.9 (95% conﬁdence interval [CI],
1.6-2.3), 3.5 (95% CI, 3.1-4.0), and 5.7 (95% CI, 5.0-
6.3) for IC subjects and 11.7 (95% CI, 11.1-12.3), 18.3
(95% CI, 17.5-19.1), and 24.4 (95% CI, 23.4-25.3) for
CLI subjects (Fig 1). Event rates for all-cause andCV-related mortality, myocardial infarction, and stroke
are displayed in Fig 1. No trends for changes in event rates
were found for myocardial infarction, stroke, and
CV-related or all-cause mortality during the study period
(data not shown).
Among all studied patients, cause of death was classi-
ﬁed as CV related in 51.8%. Death due to neoplasms was
tripled among IC patients compared with CLI patients
(30.6% vs 10.9%). By contrast, endocrine and metabolic
disease (diabetes mellitus) as underlying cause of
death was tripled for CLI subjects (12.5% vs 4.9%;
Supplementary Table III, online only).
The Cox multivariable proportional regression revealed
similar risk factors for IC and CLI; previous myocardial
infarction, ischemic stroke, and heart failure were associ-
ated with the highest risk for a new CV event. Renal failure
was associated with the highest risk among CLI subjects.
Concomitant medication with beta-blockers, calcium chan-
nel blockers, and strong opioids was associated with
increased CV death event rate, whereas statin therapy was
associated with decreased rates of CV death events in
both IC and CLI patients. Treatment with low-dose acetyl-
salicylic acid (aspirin) did not relate to the risk of the
primary composite end point in the multivariable Cox
regression model (Table III). Unadjusted hazard ratios
(HRs) for all variables explored in the Cox multivariable
proportional regression are available in Supplementary
Table IV (online only).
Medication. Among CLI patients, the use of aspirin
increased from 62% at baseline to a maximum of 71%
within 3 months after intervention (Table II; Fig 2). The
use of clopidogrel and statins increased from 7% to 26% and
Fig 1. Kaplan-Meier estimates of the risk of the primary composite end point (myocardial infarction, ischemic stroke,
or cardiovascular [CV] death), all-cause mortality, and myocardial infarction and ischemic stroke after revascularization,
separated by peripheral artery disease (PAD) stage. CI, Conﬁdence interval; CVD, cardiovascular disease; HR, hazard
ratio.
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patients for aspirin, clopidogrel, and statins were 76% to
80%, 8% to 21%, and 73% to 77%, respectively. The index
revascularization did not affect use of beta-blockers or
ARBs and ACEIs in either of the subgroups.
BMT was offered to 4524 (65%) of all IC patients
and to 5305 (45%) of all CLI patients (Table II). The pro-
portion of patients receiving BMT after revascularization
was relatively unchanged during the 5 years studied (Fig 3).DISCUSSION
This population-based large cohort study on the risk of
CV events and contemporary secondary preventive drug
treatment patterns in revascularized PAD patients has
four main ﬁndings. First, CV event rates and mortality rates
for revascularized PAD patients are still high without
trends of reduction during the study period. Second,
concomitant morbidities with coronary disease, heart fail-
ure, and renal failure were signiﬁcantly associated with
CV events. Third, a large proportion of patients did not
receive recommended secondary preventive drug treat-
ment, and no improvement in the proportion of patients
receiving BMT was observed during the study period.Last, treatment with aspirin was not associated with CV
event reduction in multivariable analysis. By contrast, statin
use was highly protective.
The CV event rates at 12 and 36 months after the index
revascularization procedure were 5% and 14% for patients
with IC and 17% and 34% for patients with CLI, respec-
tively. During past decades, the negative inﬂuence of con-
current risk factors for the PAD patients has become more
recognized, and it could have been assumed that modern
pharmacologic treatments should positively inﬂuence the
CV event rate. The persistently high event rates might, at
least partly, be explained by change in selection of patients
for revascularization with new available minimally invasive
techniques together with underuse or poor efﬁcacy of avail-
able preventive drugs. Comorbidities with myocardial
infarction, stroke, heart failure, and renal failure were highly
associated with risk for new CV events after revasculariza-
tion. This emphasizes the need for close monitoring before
and after intervention to improve overall outcome for this
group of patients. Diabetes mellitus, on the other hand,
was associated with a lower risk than expected, particularly
for patients with CLI (HR, 1.18; 95% CI, 1.10-1.26). All-
cause mortality was in line with other similar recent surveys,
and a diagnosis of IC was associated with improved overall
Table III. Finala Cox multivariable proportional regression model of risk factors for a composite end point event
(myocardial infarction, stroke, or cardiovascular [CV] death)
IC CLI
HR 95% CI P value HR 95% CI P value
Baseline
Male gender 1.26 1.09-1.44 .001 1.14 1.06-1.23 <.001
Age (per year) 1.04 1.03-1.05 <.001 1.04 1.03-1.04 <.001
Comorbidity
Myocardial infarction 1.40 1.17-1.66 <.001 1.50 1.38-1.63 <.001
Heart failure 1.56 1.30-1.88 <.001 1.50 1.38-1.62 <.001
Angina pectoris 1.15 0.99-1.34 .068 1.10 1.01-1.18 .023
Ischemic stroke 1.59 1.30-1.94 <.001 1.32 1.21-1.44 <.001
Transient ischemic attack 1.37 1.08-1.73 .008 1.14 1.01-1.28 .037
Diabetes mellitus 1.33 1.15-1.53 <.001 1.18 1.10-1.26 <.001
Respiratory insufﬁciency 1.19 0.99-1.45 .070 1.11 1.01-1.23 .030
Renal failure 1.57 1.37-1.79 <.001
Bleeding 1.29 1.03-1.63 .027 1.16 1.05-1.28 .003
Medication
Warfarin 0.84 0.75-0.94 .002
Statins 0.70 0.61-0.81 <.001 0.76 0.70-0.81 <.001
Beta-blockers 1.18 1.02-1.37 .022 1.17 1.08-1.26 <.001
Calcium channel blockers 1.18 1.03-1.35 .019
CI, Conﬁdence interval; CLI, critical limb ischemia; HR, hazard ratio; IC, intermittent claudication.
aRemaining variables contributing to the model after the ﬁnal backward stepwise procedure. Factors with P value < .20 in univariable analysis were considered
for inclusion in multivariable analysis.
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20%; Fig 1).23 Strikingly, our reported mortality data were
also similar to a previous Swedish study preformed in
1970 to 1994.24 By contrast, coronary heart disease mortal-
ity in Sweden decreased by 67.4% in men and 65.1% in
women between 1987 and 2009.25
Only 45% of CLI and 65% of IC patients were offered
BMT preoperatively (Table II). One month after revascu-
larization, antiplatelets, statins, ACEIs/ARBs, and beta-
blockers were used by 81%, 77%, 57%, and 46% of the
IC patients and by 71%, 61%, 57%, and 52% of the CLI pa-
tients (Fig 2). These treatment patterns for intervened
PAD patients are consistent with data from the United
States.26 However, the corresponding numbers after coro-
nary revascularization in Sweden in 2014 were 90%, 92%,
81%, and 86%.27 A reason that patients with PAD are less
intensively treated compared with heart patients may be
the lack of data to support pharmacologic treatment for
this population. Another reason is possibly that PAD
patients are not being recognized as a high-risk group
among cardiologists and primary care physicians. Last,
cardiologists may be more active in commencing pharma-
cologic treatment compared with vascular surgeons, who
are largely responsible for the care of PAD patients in
Sweden. This calls for increased awareness and improved
pharmacologic management in this group of largely over-
looked patients. Few changes were seen with regard to
the use of beta-blockers and ACEIs/ARBs in the perioper-
ative period. Antiplatelet therapy and statins were, on the
other hand, prescribed with increasing frequency at the
time of hospitalization, which indicates that this treatmentis mostly initiated by hospital-based vascular surgeons. Our
data also show that revascularized patients seem to adhere
to hospital-initiated treatment at 1 year.
Treatment with aspirin was not associated with a reduc-
tion in CV events in our cohort. This is in accordance with
a meta-analysis performed by Berger et al, in which treat-
ment with antiplatelets alone or in combination with dipyr-
idamole did not signiﬁcantly decrease CV events.28 Despite
the lack of compelling evidence for reduction of CV events
in a PAD setting, aspirin was the most frequently used drug
in our cohort, as it is worldwide.28 Aspirin is also the only
drug with a level I recommendation in available guidelines
for PAD management.9-12 There may be several reasons
that the atherosclerosis in limbs, contrary to other vascular
territories, is less responsive to antiplatelet therapy, such as
inherent platelet activation, extensive atherosclerosis, and
high inﬂammatory burden.29-31 Further studies with the
aim of investigating the effects of newer and more potent
antiplatelets in PAD populations are warranted.
The use of beta-blockers in the perioperative phase of
noncardiac surgery is controversial. A newly published
analysis showed no impact on patients with few risk fac-
tors.32 In our data set, the use of beta-blockers was even
slightly negatively associated with CV outcome.
Evidence suggests that the use of ACEIs/ARBs may
offer protection against CV events beyond what would
be expected from blood pressure lowering only.33,34 The
Heart Outcomes Prevention Evaluation (HOPE) study
demonstrated that the CV events were reduced by
14% to 19%, depending on ankle-brachial index level.35
However, our data do not support these ﬁndings, as
Fig 2. Persistence to preventive drug treatment for intermittent claudication (IC) and critical limb ischemia (CLI).
ACEi, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Fig 3. Time trends for best medical treatment (BMT; antiplatelet
or anticoagulant therapy and statin treatment) 1 month after
revascularization of claudication and critical lower limb ischemia
patients.
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for CV events in our model. This ﬁnding could be due to
selection of patients; ACEIs/ARBs could be more
frequently used by patients with a higher atherosclerotic
burden and therefore at higher risk for CV events.
Statins were the only drug in this survey that was mark-
edly associated with a reduction in CV events (HR, 0.76;
95% CI, 0.71-0.81; P < .001). Similar cardioprotective ef-
fects in PAD patients and, in addition, plausible effects on
leg symptoms in IC have previously been demon-
strated.36,37 Overall, <60% of patients were offered statins
preoperatively (Table II) in our cohort, with only a small
change postoperatively, particularly among patients with
CLI. The gap between international guideline recommen-
dations and “real-world” clinical implementation needs to
be addressed, and a way forward may be to recommend
statin treatment for all PAD patients, regardless of plasma
cholesterol levels.
Efforts should be made for a holistic management,
including both the reduction of adverse CV events and
the improvement of leg symptoms. As for leg symptoms,
very few claudicants were offered cilostazol (2%) despite
available randomized data on improvement of walking dis-
tance38 and health-related quality of life.39 A recent sys-
tematic review concluded that both naftidrofuryl oxalateand cilostazol are effective treatment options in IC.40 An
increased use of such vasoactive drugs in IC may reduce
the proportion of patients ultimately requiring invasive
interventions.
This study comprises a contemporary national audit of
revascularized PAD patients. The use of large and
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1016 Sigvant et al October 2016population-based registries in combination with unique
identiﬁcation numbers facilitates tracking of each patient
through the health care system, with highly accurate data
from the Swedish mandatory national registries. Limita-
tions include the incomplete data on smoking habits
(48% missing data in the Swedvasc registry), and as for all
observational registry studies, the inherent design of our
study has limitations. However, all analyzed data were pro-
spectively collected in large population-based registries,
and we therefore would argue that the presented results
reasonably mirror current real-world CV outcomes and
pharmacologic treatment patterns for revascularized PAD
patients, at least in Sweden.
CONCLUSIONS
Revascularized PAD patients are still at a high risk for
CV events and mortality, without a declining time trend
during the observation period. One in three CLI patients
experienced a CV event within 3 years after revasculariza-
tion. Comorbidity in other vascular territories was associ-
ated with high risk for CV events after revascularization.
Use of statins was associated with reduced CV events but
was offered only to just more than half of patients with
PAD. Aspirin was the most commonly used drug but was
not associated with CV event reduction in multivariable
analyses. Thus, there is an urgent need for a more effective
implementation of currently recommended medications as
well as for a continued search after more effective pharma-
cologic treatment options in PAD.
This report would not have been possible without the
generous contribution of data to the Swedvasc registry by
Swedish vascular surgeons and interventional radiologists.
The Steering Committee of the Swedvasc: Katarina
Björses, Lena Blomgren, Erik Wellander, Joachim Starck,
Magnus Jonsson, and Jakob Swanberg.
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Supplementary Table I (online only). Diagnostic codes and identiﬁers used in the extraction of baseline data
Disease group ICD-10 Treatment
Renal artery stenosis I70.1
Aortic aneurysm I71
Arterial embolism and thrombosis I74.0-2
Pulmonary embolism I26
Diabetes E10-E14 A10
Hypertension I10 C02C, C09C, C09D, C09A, C09B,
C08C, C03A, C03EA01
Myocardial infarction I21-I22
Unstable angina I20.0
Angina pectoris I20.1, I20.8, I20.9
Ischemic stroke I63-I64
Transient ischemic attack G45.0-3, 8-9
Heart failure I50
Atrial ﬁbrillation I48
Major organ-speciﬁc bleedings D62.9, I60-62, I85.0, K22.6
K25.0, K25.2, K25.4, K25.6
K26.0, K26.2, K26.4, K26.6
K27.0, K27.2, K27.4, K27.6
K28.0, K28.2, K28.4, K28.6
K29.0, K62.5, K92.0-K92.2
Chronic renal insufﬁciency I15.0, I15.1, N03, N04, N05, N11,
N18.4, N18.5, Q60, Q61, Z49.1, Z99.2
Pulmonary insufﬁciency J44
Cancer C00-C99
Dementia F00-02, F03.9
ICD-10, International Classiﬁcation of Diseases, Tenth Revision.
Supplementary Table II (online only). Medication of interest in the study
Medication group High-level ATC Medication subgroup Lower level ATC
Antiplatelets B01AC Clopidogrel B01AC04
Prasugrel B01AC22
Ticagrelor B01AC24
Low-dose aspirin B01AC06
Cilostazol B01AC
Dual antiplatelets Low-dose aspirin þ any of clopidogrel,
prasugrel, or ticagrelor
Anticoagulants B01AA Warfarin B01AA03
B01AE
B01AF
Antidyslipidemics C10A Statins C10AA
Fibrates C10AB
Antihypertensives Beta-blockers C07
ACEIs C09A, C09B
ARBs C09C, C09D
Calcium channel blockers C08
Diuretics C03
Antidiabetics A10 NIAD A10B
Insulin A10A
Analgesics N02 Opioids N02A
Strong opioids N02A excluding N02AA59
and N02AX02
Other
Nitrates C01
Low-molecular-weight heparin B01AB
ACEIs, Angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; ATC, Anatomical Therapeutic Chemical classiﬁcation system;NIAD,
non-insulin antidiabetic drug.
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Supplementary Table III (online only). Primary cause of death
IC, No. (%) CLI, No. (%) Total, No. (%)
Circulatory system 385 (45.94) 2437 (52.8) 2822 (51.80)
Neoplasms 256 (30.55) 500 (10.85) 756 (13.88)
Endocrine and metabolic diseases 41 (4.89) 576 (12.49) 617 (11.33)
Diseases of respiratory system 48 (5.73) 294 (6.38) 342 (6.28)
Diseases of the digestive system 27 (3.22) 159 (3.45) 186 (3.41)
Infectious disease 16 (1.91) 151 (3.28) 167 (3.07)
Abnormal clinical and laboratory ﬁndings 18 (2.15) 116 (2.52) 134 (2.46)
Diseases of the genitourinary system 7 (0.84) 97 (2.10) 104 (1.91)
Mental disorders 6 (0.72) 66 (1.43) 72 (1.32)
Diseases of the skin and musculoskeletal system 2 (0.24) 61 (1.32) 63 (1.16)
Other causes 32 (3.82) 153 (3.32) 185 (3.40)
CLI, Critical limb ischemia; IC, intermittent claudication.
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Variable
Claudication
HR 95% CI Cov
Open vs endovascular 1.01 0.86-1.19
Male gender 1.29 1.13-1.48
Age (per year 1.05 1.04-1.06
Previous smokers vs nonsmokers 0.76 0.59-0.97
Current smokers vs nonsmokers 0.91 0.65-1.26
Diabetes 1.50 1.31-1.72
Hypertension 1.67 1.37-2.03
Myocardial infarction 2.00 1.71-2.34
Unstable angina pectoris 1.74 1.45-2.10
Angina pectoris 1.65 1.44-1.89
Ischemic stroke 2.17 1.79-2.63
Transient ischemic attack 1.88 1.50-2.36
Heart failure 2.59 2.21-3.04
Atrial ﬁbrillation 2.05 1.74-2.43
Major organ-speciﬁc bleedings 1.74 1.39-2.17
Liver disease 1.26 0.41-3.92
Renal disease 1.80 1.27-2.54
Respiratory insufﬁciency 1.39 1.15-1.67
Cancer 0.99 0.83-1.19
Aspirin 0.79 0.69-0.91
Warfarin 1.83 1.45-2.31
Statins 0.76 0.66-0.88
Beta-blockers 1.60 1.40-1.82
ACEIs 1.21 1.06-1.39
ARBs 1.04 0.90-1.22
Calcium channel blockers 1.27 1.11-1.44
Strong opioids 1.52 1.21-1.90
Heparin 1.62 1.22-2.14
ACEIs, Angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor bf primary composite cardiovascular (CV) end point
Critical lower limb ischemia
ariate P value HR 95% CI Covariate P value
.891 0.85 0.78-0.92 <.001
<.001 1.09 1.02-1.16 .013
<.001 1.04 1.04-1.05 <.001
.068 0.86 0.78-0.95 <.001
0.68 0.60-0.78
<.001 1.18 1.10-1.26 <.001
<.001 1.47 1.32-1.64 <.001
<.001 2.01 1.87-2.17 <.001
<.001 1.36 1.22-1.51 <.001
<.001 1.56 1.45-1.67 <.001
<.001 1.57 1.44-1.71 <.001
<.001 1.45 1.29-1.63 <.001
<.001 2.29 2.13-2.45 <.001
<.001 2.05 1.91-2.20 <.001
<.001 1.39 1.26-1.53 <.001
.686 1.45 0.99-2.14 .056
.001 1.73 1.52-1.97 <.001
.001 1.17 1.07-1.29 .001
.916 1.17 1.08-1.27 <.001
.001 0.95 0.89-1.02 .139
<.001 1.32 1.19-1.46 <.001
<.001 0.72 0.67-0.77 <.001
<.001 1.54 1.44-1.64 <.001
.006 1.12 1.05-1.20 .001
.587 0.97 0.89-1.05 .472
<.001 0.98 0.91-1.05 .504
<.001 1.38 1.28-1.47 <.001
.001 1.04 0.92-1.18 .505
lockers; CI, conﬁdence interval; HR, hazard ratio.
Supplementary Fig (online only). Age distribution for claudi-
cation and critical lower limb ischemia patients at admission for
revascularization.
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